What Beyaz Treats: Main Uses and Benefits

Beyaz (Drospirenone/Ethinyl Estradiol/Levomefolate Calcium) is commonly used in situations involving contraception, in addition to addressing specific, hormonally related health concerns and nutritional support. The medication is relevant across four core therapeutic domains that involve both reproductive and symptomatic needs. Its application includes contexts involving recurrent or episodic manifestations, and it is commonly used when symptoms become more noticeable.

The drug's primary uses include providing supportive systemic contraceptive protection, managing the severe emotional and physical symptoms of Premenstrual Dysphoric Disorder (PMDD), therapeutic treatment for moderate acne vulgaris, and proactive folate status maintenance for nutritional support. The inclusion of the folate component, Levomefolate Calcium, provides supportive relief in situations where there are concerns about nutritional status, and may assist with maintaining functional stability, which is associated with supporting general well-being during symptomatic phases.

“This formulation is relevant when supportive symptom management is appropriate alongside the need for pregnancy prevention.”

Quick Fact: Relief for Cyclical Discomfort and Skin Symptoms Beyaz is commonly used to help with family planning, while assisting with the management of symptoms related to severe cyclical distress and hormonally driven skin changes.

Official Population Eligibility

Beyaz is indicated for use only by females of reproductive potential (post-menarche) for pregnancy prevention. Use for other indicated conditions, such as moderate acne vulgaris (age ge 14 years) or symptoms of Premenstrual Dysphoric Disorder (PMDD), is conditional upon the patient choosing to use an oral contraceptive for birth control.

Absolute Contraindications (Cannot Use)

Official regulatory documents mandate that Beyaz must not be used by individuals with the following conditions or characteristics:

Age and Physiological Status Restrictions

Use is not indicated for patients who are pre-menarcheal (children) or postmenopausal (older adults). The medication is also not recommended for women who are breastfeeding, as combined hormonal contraceptives may affect milk production.

Interactions with other medicines and products for Beyaz

The official regulatory profile for Beyaz (Drospirenone/Ethinyl Estradiol/Levomefolate Calcium) is defined by pharmacokinetic and pharmacodynamic constraints. Co-administration is strictly contraindicated with certain Hepatitis C combination regimens containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the documented risk of liver enzyme elevation. Additionally, use is contraindicated for women over 35 years of age who smoke due to serious cardiovascular event risk.

The progestin Drospirenone has an antimineralocorticoid effect, posing a pharmacodynamic risk of hyperkalemia (elevated potassium levels) when combined with other potassium-elevating medications. These include potassium-sparing diuretics, ACE inhibitors, Angiotensin-II receptor antagonists, and NSAIDs. For women on long-term treatment with these medicines, regulatory guidelines mandate a serum potassium check during the first treatment cycle. The medicine must be discontinued prior to starting the contraindicated Hepatitis C regimen and can be restarted approximately two weeks after its completion. The Levomefolate Calcium component may also interact with folic acid antagonists.

How Beyaz Works

Beyaz's hormonal components engage with receptors in the hypothalamic-pituitary axis, establishing negative feedback that suppresses the release of gonadotropins, specifically follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This action initiates a cascade that results in the inhibition of follicular maturation and the prevention of the mid-cycle LH surge. Furthermore, these hormonal components modulate local tissue responses, resulting in increased cervical mucus viscosity and altered endometrial morphology.

The progestin component, drospirenone, acts as a competitive antagonist at both the mineralocorticoid and androgen receptors. Blocking the mineralocorticoid receptor modulates aldosterone's action, resulting in increased renal excretion of sodium and water. Inhibition at the androgen receptor competitively prevents the binding of endogenous androgens to their respective sites.

The medication also contains levomefolate, the biologically active form of folate ( 5-MTHF). This compound directly supports the one-carbon metabolic cycle, where it functions as a required cofactor. This mechanism provides the necessary cofactors for the efficient operation of core cellular synthetic pathways, which facilitates nucleic acid synthesis and the methylation cycle.

The administration of Beyaz involves taking the film-coated tablets orally on a continuous, 28-day cycle, following the order designated on the blister pack.

Administration Details

Starting and Continuing the Cycle

Beyaz may be started using two protocols:

1. Day 1 Start: Begin the first pink tablet on the first day of the menstrual period.
2. Sunday Start: Begin the first pink tablet on the first Sunday after the start of the menstrual period.

After completing the 28 tablets, begin a new pack the very next day, regardless of whether a menstrual period has occurred or is still in progress. The procedural rule is that if the drug is started later than Day 1 of the menstrual cycle or later than the day following the last light orange tablet of a previous cycle, a non-hormonal back-up contraceptive method must be used for the first 7 consecutive days of pink tablet administration.

Missed Tablets

The failure rate may increase if tablets are missed. If a single tablet is missed, it should be taken as soon as remembered. For detailed instructions regarding two or more missed tablets, the relevant product directions should be followed.

Research evidence / Overview of studies for Beyaz

Evidence for Pregnancy Prevention

Research for this use involves large, multi-center studies that were conducted to explore the clinical evaluation for the hormonal components concerning unintended pregnancy. The primary objective in these studies was to monitor the occurrence of unintended pregnancy, which was then calculated as a rate over one year of use. The evidence supporting this use was primarily gathered from studies of the original formulation, which contained the same two hormones but excluded the added folate component.

The findings from these large-scale studies describe patterns observed concerning the occurrence of pregnancy among healthy women of reproductive age who used the pill for about one year (13 menstrual cycles). This research contributes to the broader body of evidence regarding the use of this type of contraception.

Evidence for Studies Related to Premenstrual Dysphoric Disorder (PMDD)

Studies exploring symptom patterns related to PMDD, which examined the hormonal components, utilized randomized, placebo-controlled trials (RCTs). Researchers used daily symptom diaries and assessment tools to measure outcomes related to emotional and physical discomfort in women with prospectively confirmed PMDD. These studies were generally short-term, typically three menstrual cycles, meaning longer-term outcomes or patterns are not fully established.

Research on Folate Status Maintenance

The inclusion of Levomefolate Calcium, an active form of folate, was evaluated in randomized, double-blind, comparative trials. Researchers examined whether the co-administration of the folate component was associated with changes in biochemical markers of folate status, such as Red Blood Cell (RBC) folate and plasma folate concentrations, in healthy women. The studies reported measurements of these folate markers, with data showing patterns related to the concentrations of these markers over approximately 24 weeks of use. It is important to note that no clinical trial has been conducted to directly study the effect of the Beyaz formulation on reducing the risk of neural tube defects (NTDs); the link to NTD risk reduction is an inference based on general public health recommendations regarding folate supplementation.

Common questions about Beyaz (FAQ)

Q: What is Beyaz used for?

A: Beyaz is an oral contraceptive (birth control pill) used to prevent pregnancy. It is also approved to treat the symptoms of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive for birth control, and to treat moderate acne in women who are at least 14 years old, have started their menstrual period, and desire an oral contraceptive for birth control. Additionally, Beyaz contains a form of the B vitamin folate (levomefolate calcium) to raise folate levels in women who choose to use an oral contraceptive for birth control.

Q: How does Beyaz work to prevent pregnancy?

A: Beyaz is a combination hormonal contraceptive containing two hormones, drospirenone and ethinyl estradiol. It works primarily by three actions: it stops the release of an egg from the ovary (ovulation), thickens the cervical mucus to make it harder for sperm to reach the egg, and changes the lining of the uterus (endometrium) to prevent the implantation of a fertilized egg.

Q: What is the benefit of the added folate (levomefolate calcium) in Beyaz?

A: The active ingredient levomefolate calcium is a form of the B vitamin folate (folic acid). Folate is important for healthy cell growth and division. The purpose of including levomefolate calcium is to increase folate levels in women who use the birth control pill. Adequate folate levels are especially important before and during pregnancy to help prevent certain birth defects of the brain and spine (neural tube defects), although Beyaz should not be taken when a woman is already pregnant.

Q: What are some of the common side effects of Beyaz?

A: Common side effects can include nausea, headache, breast tenderness, irregular bleeding or spotting, and mood changes. These side effects are often mild and may improve after the first few months as the body adjusts to the medication. If side effects persist or are severe, a healthcare provider should be consulted.

How to Store and Dispose of Beyaz (Drospirenone/Ethinyl Estradiol/Levomefolate Calcium)

Beyaz must be stored at Controlled Room Temperature, defined as 20^circC to 25^circC (68^circF to 77^circF), with regulatory allowance for temporary temperature excursions. The medicine should be stored away from moisture and heat and kept in a dry place. Patients are directed to store the tablets in their original container and not in the bathroom due to temperature and humidity variations.

For safety, the medication must be stored out of the sight and reach of children.

To dispose of unused or expired Beyaz, general FDA guidelines recommend that patients not flush the tablets. Instead, they should be mixed with an undesirable substance (like coffee grounds or kitty litter), sealed in a bag or container, and discarded in the household trash.